期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

房颤抗心律失常药物治疗策略的选择 被引量：1

Treatment strategy of antiarrhythmic drugs in atrial fibrillation
原文传递
导出
摘要 房颤(AF)病例分布广,发病率增长快,相关临床后果严重,如脑卒中、生活质量及活动能力下降、住院率增加、左室功能下降乃至死亡等。对AF患者的抗心律失常药物治疗,必须面对两种治疗策略的选择。本文综合近期陆续发表的一些临床研究结果,初步探讨临床治疗策略选择。 The prevalence of atrial fibrillation （AF） is extensively increased. AF can cause a number of clinical serious outcomes, including stroke, life quantity and movable ability descent, hospitalization rate increment, left ventricular dysfunction and death. Based on updated clinical evidence, this review presents a solution for the treatment strategy of antiarrhythmic drugs in AF patients.
作者 郑刚
机构地区 天津市第三医院心内科天津市老年病研究所
出处 《世界临床药物》 CAS 2012年第6期325-329,350,共6页 World Clinical Drug
关键词 房颤 抗心律失常药物 节律控制 心室率控制 atrial fibrillation antiarrhythmic drug rhythm control rate control
分类号 R972.2 [医药卫生—药品]
  • 相关文献

参考文献28

  • 1Bosch RF, Kirch W, Theuer JD, et al. Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: Prospective non-interventional study[J]. Int J Cardiol, 2012 Apr 2. EEpub ahead of print], http://www.ncbi. nlm.nih.gov/pubmed/22475841.
  • 2Chiang CE, Zhang S, Tse HF, et al. Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation[J]. Int J Cardiol, 2012 Jan 10. [Epub ahead of print], http://www.ncbi.nlm.nih.gov/pubmed/22240753.
  • 3Lip GY, Tse HF, Lane DA. Atrial fibrillation [J]. Lancet, 2012, 379 (9816) : 648-661.
  • 4Hirano K, Yamashita T, Suzuki S, et al. Relationship between 24-h Holter recordings and clinical outcomes in patients with permanent atrial fibrillation[J]. J Cardiol, 2012 Mar 21. [Epub ahead of print] .http://www.ncbi.nlm.nih.gov/ pubmed/22445594.
  • 5Oliveira LH, Mallmann FB, Botelho FN, et al. Cross-sectional study of treatment strategies on atrial fibrillation [J]. Arq Bras Cardiol,2012 Feb 29. pii: S0066-782X2012005000020. [Epub ahead of print].
  • 6Amerena J, Chen SA, Sriratanasathavom C, et al. Insighte into management of atrial fibrillation in Asia Pacific gained from baseline data from Registry on cardiac rhythm disorders (RecordAF-Asia Pacific) registry [J].Am J Cardiol, 2012, 109(3) : 378-382.
  • 7Schilling RJ. Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs [J]. Heart, 2010, 96 (5): 333-338.
  • 8Pamukcu B, Lip GY. Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study[J]. Expert Opin Pharmacother, 2010, 11 (17): 2775-2778.
  • 9Christiansen CB, Torp-Pedersen C, Khyper L. Impact of dronedarone in atrial fibrillation and flutter on stroke reduction[J]. Clin Interv Aging, 2010, 5 (4) : 63-69.
  • 10Oyetayo OO, Rogers CE, Hofmann PO. Dronedarone: a new antiarrhythmic agent[J]. Pharmacotherapy, 2010, 30(9):904-915.

二级参考文献13

  • 1Hohnloser SH, Kuek KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF) : a randomised trial. Lancet,2000,356 : 1789-1794.
  • 2Carlsson J,Miketic S, Windeler J, et al. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol, 2003, 41:1690-1696.
  • 3Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med,2002,347 : 1825-1833.
  • 4Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med ,2002,347 : 1834-1840.
  • 5Chung MK, Shemanski L, Sherman DG, et al. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol,2005,46 : 1891-1899.
  • 6Freudenberger RS, Wilson AC, Kostis JB. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol, 2007,100:247-252.
  • 7Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med,2008,358: 2667 -2677.
  • 8Crijns HJ. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs, 2005,65: 1651- 1667.
  • 9Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med ,2007,357:987-999.
  • 10Hohnloser SH, Connolly SJ, Crijns HJ, et al. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol, 2008,19:69-73.

共引文献1

同被引文献29

引证文献1

二级引证文献2

世界临床药物
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部